Zeinab Shirvani-Farsani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeinab Shirvani-Farsani has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Taheri
Institute of Human Genetics, Jena University Hospital, Jena, Germany; Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
12 shared publications - Mehrdad Behmanesh
Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
8 shared publications - Soudeh Ghafouri-Fard
Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 shared publications Bahar Naghavi Gargari
Department of Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publicationsZahra Abedi Kichi
Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IR Iran
4 shared publications- Mahdieh Mehrab Mohseni
Department of Cell and Molecular Biology, Faculty of Life Sciences and Technology, Shahid Beheshti University, Tehran, Iran
3 shared publications
Latest Publications
- 21 October 2026
- Published by American Chemical Society (ACS) in ACS Sensors
Genetic Biosensors for High-Throughput Biomedical Applications: Challenges and Advances
Genetic biosensors represent a particularly promising class of bioengineered instruments designed to enable accurate, real-time monitoring of cellular and molecular processes, with especially strong relevance to high-throughput biomedical workflows. In this review, we provide a systematic, clearly structured overview of the field, covering the fundamental design principles that form the basis of today's platforms. We focus in particular on DNA-based, RNA-based, and CRISPR-based architectures while also examining engineered synthetic biology circuitry, and we place these foundational concepts in the context of more recent advances. These developments encompass improved sensitivity, increased scalability, and broader functionality for multiplexed detection. Beyond summarizing technological progress, we critically evaluate challenges that remain deeply embedded at both technical and biological levels, including limitations driven by signal-to-noise ratio constraints, practical difficulties in delivering probes into cells, and relatively restricted dynamic ranges. Taken together, these issues continue to hinder widespread, routine clinical adoption. Importantly, rather than presenting the topic only as a catalog of improvements, we argue for a unifying framework: the convergence of artificial intelligence and synthetic biology is actively reshaping biosensor engineering, moving it away from a largely empirical, trial-and-error approach toward a more reliable, data-driven discipline. To convert this conceptual shift into tangible outcomes, we also outline a practical implementation framework aimed at reducing the distance between research activities and real-world deployment. This framework emphasizes the need for scalable manufacturing processes, robust and reproducible clinical validation, and regulatory pathways capable of evolving as new evidence emerges. An integrated strategy of this kind is therefore essential for fully realizing the potential of real-time, multichannel biosensing platforms in both complex clinical diagnostics and point-of-care environments.
- 21 October 2026
- Published by American Chemical Society (ACS) in ACS Sensors
Genetic Biosensors for High-Throughput Biomedical Applications: Challenges and Advances
Genetic biosensors represent a particularly promising class of bioengineered instruments designed to enable accurate, real-time monitoring of cellular and molecular processes, with especially strong relevance to high-throughput biomedical workflows. In this review, we provide a systematic, clearly structured overview of the field, covering the fundamental design principles that form the basis of today's platforms. We focus in particular on DNA-based, RNA-based, and CRISPR-based architectures while also examining engineered synthetic biology circuitry, and we place these foundational concepts in the context of more recent advances. These developments encompass improved sensitivity, increased scalability, and broader functionality for multiplexed detection. Beyond summarizing technological progress, we critically evaluate challenges that remain deeply embedded at both technical and biological levels, including limitations driven by signal-to-noise ratio constraints, practical difficulties in delivering probes into cells, and relatively restricted dynamic ranges. Taken together, these issues continue to hinder widespread, routine clinical adoption. Importantly, rather than presenting the topic only as a catalog of improvements, we argue for a unifying framework: the convergence of artificial intelligence and synthetic biology is actively reshaping biosensor engineering, moving it away from a largely empirical, trial-and-error approach toward a more reliable, data-driven discipline. To convert this conceptual shift into tangible outcomes, we also outline a practical implementation framework aimed at reducing the distance between research activities and real-world deployment. This framework emphasizes the need for scalable manufacturing processes, robust and reproducible clinical validation, and regulatory pathways capable of evolving as new evidence emerges. An integrated strategy of this kind is therefore essential for fully realizing the potential of real-time, multichannel biosensing platforms in both complex clinical diagnostics and point-of-care environments.
- Open Access
- 2 July 2026
- Vol. 47, 102698
Circadian rhythm lncRNA NRON is dysregulated in autism spectrum disorder: an observational study
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. It is marked by difficulties in social communication and the presence of repetitive behaviors. Research has found that disruptions in the body's circadian rhythm and dopamine signaling pathways can contribute to the development of this disorder. Long non-coding RNAs (lncRNAs) are important for regulating gene expression. They have been identified as potential risk genes and diagnostic markers for ASD. This observational (case-control) study aimed to investigate and compare the expression levels of three lncRNAs related to circadian rhythm, NRON, HULC, and LINC01138, and two lncRNAs linked to dopamine signaling, MIAT and TRAF3IP2-AS1, in the peripheral blood of 30 patients with ASD and 41 healthy controls using Real-time PCR. The results showed a significant increase in NRON lncRNA expression in patients with ASD compared to healthy controls (P = 0.0048**). However, the expression level of HULC, LINC01138, MIAT, and TRAF3IP2-AS1 did not show any significant difference between these two groups (P > 0.05). Additionally, when analyzing by sex, affected males had significantly higher NRON expression than control males (P = 0.002**). There was also a significant correlation between the expression of MIAT and TRAF3IP2-AS1 and the age of ASD patients. Moreover, ROC curve analysis suggested that NRON could serve as a diagnostic marker for ASD (AUC = 0.70 and P = 0.004). Overall, these findings indicate that dysregulation of NRON in peripheral blood is associated with ASD. While the functional relevance of this peripheral signature to CNS pathophysiology remains to be established, NRON may serve as a candidate for future peripheral biomarker discovery attempts.
- 2 July 2026
- Vol. 47, 102698
Open AccessCircadian rhythm lncRNA NRON is dysregulated in autism spectrum disorder: an observational study
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. It is marked by difficulties in social communication and the presence of repetitive behaviors. Research has found that disruptions in the body's circadian rhythm and dopamine signaling pathways can contribute to the development of this disorder. Long non-coding RNAs (lncRNAs) are important for regulating gene expression. They have been identified as potential risk genes and diagnostic markers for ASD. This observational (case-control) study aimed to investigate and compare the expression levels of three lncRNAs related to circadian rhythm, NRON, HULC, and LINC01138, and two lncRNAs linked to dopamine signaling, MIAT and TRAF3IP2-AS1, in the peripheral blood of 30 patients with ASD and 41 healthy controls using Real-time PCR. The results showed a significant increase in NRON lncRNA expression in patients with ASD compared to healthy controls (P = 0.0048**). However, the expression level of HULC, LINC01138, MIAT, and TRAF3IP2-AS1 did not show any significant difference between these two groups (P > 0.05). Additionally, when analyzing by sex, affected males had significantly higher NRON expression than control males (P = 0.002**). There was also a significant correlation between the expression of MIAT and TRAF3IP2-AS1 and the age of ASD patients. Moreover, ROC curve analysis suggested that NRON could serve as a diagnostic marker for ASD (AUC = 0.70 and P = 0.004). Overall, these findings indicate that dysregulation of NRON in peripheral blood is associated with ASD. While the functional relevance of this peripheral signature to CNS pathophysiology remains to be established, NRON may serve as a candidate for future peripheral biomarker discovery attempts.
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Altered expression of KCNQ1OT1 and ZEB1-AS1 lncRNAs in autism spectrum disorder: A case–control study
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with a significant genetic basis, although its multifactorial etiology remains poorly understood. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play critical roles in gene regulation and in modulating key signaling pathways, including extracellular matrix (ECM), which are crucial for neural development. In this study, we examined the expression levels of three lncRNAs; TGFβ2-AS1, KCNQ1OT1, and ZEB1-AS1; in peripheral blood samples collected from 30 individuals with ASD and 41 age and gender matched healthy controls. Total RNA was extracted, and gene expression was quantified using real-time quantitative PCR. The results revealed a significant upregulation of ZEB1-AS1 (approximately 20-fold increase, p < 0.0001) and a striking downregulation of KCNQ1OT1 (nearly 30-fold decrease, p < 0.0001) in ASD patients. In contrast, TGFβ2-AS1 expression showed no significant change. A positive correlation was also observed between KCNQ1OT1 expression and patient age. Receiver operating characteristic (ROC) curve analyses demonstrated strong diagnostic potential for KCNQ1OT1 and ZEB1-AS1, with AUC values of 0.91 and 0.88, respectively. Overall, these findings suggest that dysregulation of specific lncRNAs may contribute to ASD pathogenesis and highlight KCNQ1OT1 and ZEB1-AS1 as promising diagnostic biomarkers and potential therapeutic targets.
- 10 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Altered expression of KCNQ1OT1 and ZEB1-AS1 lncRNAs in autism spectrum disorder: A case–control study
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with a significant genetic basis, although its multifactorial etiology remains poorly understood. Emerging evidence suggests that long non-coding RNAs (lncRNAs) play critical roles in gene regulation and in modulating key signaling pathways, including extracellular matrix (ECM), which are crucial for neural development. In this study, we examined the expression levels of three lncRNAs; TGFβ2-AS1, KCNQ1OT1, and ZEB1-AS1; in peripheral blood samples collected from 30 individuals with ASD and 41 age and gender matched healthy controls. Total RNA was extracted, and gene expression was quantified using real-time quantitative PCR. The results revealed a significant upregulation of ZEB1-AS1 (approximately 20-fold increase, p < 0.0001) and a striking downregulation of KCNQ1OT1 (nearly 30-fold decrease, p < 0.0001) in ASD patients. In contrast, TGFβ2-AS1 expression showed no significant change. A positive correlation was also observed between KCNQ1OT1 expression and patient age. Receiver operating characteristic (ROC) curve analyses demonstrated strong diagnostic potential for KCNQ1OT1 and ZEB1-AS1, with AUC values of 0.91 and 0.88, respectively. Overall, these findings suggest that dysregulation of specific lncRNAs may contribute to ASD pathogenesis and highlight KCNQ1OT1 and ZEB1-AS1 as promising diagnostic biomarkers and potential therapeutic targets.
- Open Access
- 30 January 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1)
Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders
Neurodegenerative disorders involve the gradual breakdown of neurons, leading to problems with thinking, movement, and mental health. More evidence is emer
- 30 January 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1)
Open AccessEmerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders
Neurodegenerative disorders involve the gradual breakdown of neurons, leading to problems with thinking, movement, and mental health. More evidence is emer
- Open Access
- 26 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 42255
Altered expression of LINC03091 and LINC03090 LncRNAs in bipolar disorder: a case-control study
Long non-coding RNAs (lncRNAs) are widely expressed and play an essential role in gene regulation through various transcriptional and post-transcriptional mechanisms. Recent findings have highlighted the role of lncRNAs in sustaining cellular homeostasis and neurogenesis within the brain. An increasing number of reports have identified dysregulated lncRNAs linked to psychiatric disorders, including bipolar disorder (BD). We analyzed the expression levels of LRRC2-AS1, LINC03091, and LINC03090 lncRNAs in the blood samples of 50 patients with BD and 50 healthy individuals matched by age, sex, and ethnicity. RNA extraction and cDNA synthesis were performed, followed by real-time polymerase chain reaction to quantify lncRNA expression levels. Receiver operating characteristic (ROC) curve analysis was used to assess the biomarker potential. Furthermore, the relationship between gene expression levels and BD comorbidities was explored. Our findings revealed a significant enhancement in LINC03091 and LINC03090 expression in patients with BD compared with healthy subjects ( P < 0.0001 and P = 0.02, respectively). However, the expression levels of LRRC2-AS1 was not significant ( P = 0.69). ROC curve analysis indicated that LINC03091 (AUC = 0.74, P < 0.0001) and LINC03090 (AUC = 0.64, P = 0.01) expression levels could effectively differentiate patients from healthy controls. Considering these results, LINC03091 and LINC03090 may have a crucial role in BD and could serve as biomarkers for diagnostic and predictive applications.
- 26 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 42255
Open AccessAltered expression of LINC03091 and LINC03090 LncRNAs in bipolar disorder: a case-control study
Long non-coding RNAs (lncRNAs) are widely expressed and play an essential role in gene regulation through various transcriptional and post-transcriptional mechanisms. Recent findings have highlighted the role of lncRNAs in sustaining cellular homeostasis and neurogenesis within the brain. An increasing number of reports have identified dysregulated lncRNAs linked to psychiatric disorders, including bipolar disorder (BD). We analyzed the expression levels of LRRC2-AS1, LINC03091, and LINC03090 lncRNAs in the blood samples of 50 patients with BD and 50 healthy individuals matched by age, sex, and ethnicity. RNA extraction and cDNA synthesis were performed, followed by real-time polymerase chain reaction to quantify lncRNA expression levels. Receiver operating characteristic (ROC) curve analysis was used to assess the biomarker potential. Furthermore, the relationship between gene expression levels and BD comorbidities was explored. Our findings revealed a significant enhancement in LINC03091 and LINC03090 expression in patients with BD compared with healthy subjects ( P < 0.0001 and P = 0.02, respectively). However, the expression levels of LRRC2-AS1 was not significant ( P = 0.69). ROC curve analysis indicated that LINC03091 (AUC = 0.74, P < 0.0001) and LINC03090 (AUC = 0.64, P = 0.01) expression levels could effectively differentiate patients from healthy controls. Considering these results, LINC03091 and LINC03090 may have a crucial role in BD and could serve as biomarkers for diagnostic and predictive applications.
- 26 August 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (3) , 1-10
Assessment of Expression of lncRNAs in Autistic Patients
Autism is a severe neurodevelopmental condition with unknown pathobiology. Nevertheless, multiple pieces of evidence suggest long non-coding RNA (lncRNA) dysregulation may be a contributing factor to this disorder. We investigated the association between the expression of five specific lncRNAs and autism. Peripheral blood was collected from 30 children with autism and 41 healthy children. The expression levels of PCAT-29, lincRNA-ROR, LINC-PINT, lincRNA-p21, and PCAT-1 were calculated. Then, their significance as biomarkers was also evaluated. The expression of LincRNA-ROR (27 times), LINC-PINT (5.26 times), LincRNA-p21 (4.54 times), PCAT-29 (16.66 times), and PCAT-1 (25 times) genes was significantly decreased in patients compared to the control group (p values < 0.05). According to the ROC curve analysis for each lncRNA, LincRNA-ROR, LINC-PINT, LincRNA-p21, PCAT-29, and PCAT-1 lncRNAs with diagnostic power of 0.85, 0.67, 0.64, 0.74, and 0.84, respectively, could be used as diagnostic biomarkers for autism. Additionally, significant positive correlations were reported between expression levels of PCAT-1 and PCAT-29 genes. Moreover, a positive correlation was detected between expression levels of lincRNA-ROR and patients’ age. The current study shows further pieces of evidence for deregulation of lncRNAs in autistic patients that show these lncRNAs may play an important part in the pathogenesis of ASD. However, the role of lncRNA in the neurobiology of autism needs to be investigated further.
- 26 August 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (3) , 1-10
Assessment of Expression of lncRNAs in Autistic Patients
Autism is a severe neurodevelopmental condition with unknown pathobiology. Nevertheless, multiple pieces of evidence suggest long non-coding RNA (lncRNA) dysregulation may be a contributing factor to this disorder. We investigated the association between the expression of five specific lncRNAs and autism. Peripheral blood was collected from 30 children with autism and 41 healthy children. The expression levels of PCAT-29, lincRNA-ROR, LINC-PINT, lincRNA-p21, and PCAT-1 were calculated. Then, their significance as biomarkers was also evaluated. The expression of LincRNA-ROR (27 times), LINC-PINT (5.26 times), LincRNA-p21 (4.54 times), PCAT-29 (16.66 times), and PCAT-1 (25 times) genes was significantly decreased in patients compared to the control group (p values < 0.05). According to the ROC curve analysis for each lncRNA, LincRNA-ROR, LINC-PINT, LincRNA-p21, PCAT-29, and PCAT-1 lncRNAs with diagnostic power of 0.85, 0.67, 0.64, 0.74, and 0.84, respectively, could be used as diagnostic biomarkers for autism. Additionally, significant positive correlations were reported between expression levels of PCAT-1 and PCAT-29 genes. Moreover, a positive correlation was detected between expression levels of lincRNA-ROR and patients’ age. The current study shows further pieces of evidence for deregulation of lncRNAs in autistic patients that show these lncRNAs may play an important part in the pathogenesis of ASD. However, the role of lncRNA in the neurobiology of autism needs to be investigated further.
- Open Access
- 23 July 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-7
The expression analysis of long noncoding RNAs PCAT-1, PCAT-29, and MER11C in bipolar disorder
Long non-coding RNAs (lncRNAs) are transcripts with a length of usually more than 200 nucleotides (nt) that have promised functions in varied biological processes. lncRNAs participate in the regulation of differentiation, development, and function of the brain. Thus, their dysregulation might play important roles in the etiology of neurological disorders such as BD. In this study, the expression level of PCAT-1, PCAT-29, and MER11C lncRNAs was evaluated in the blood of BD patients compared to the control group. Peripheral blood mononuclear cells of 50 BD type I patients and 50 healthy individuals were isolated. The RNAs were extracted and cDNA was synthesized. Then, the expression level of the desired lncRNAs was measured through Real-Time PCR. The expression levels of PCAT-29 and MER11C lncRNAs were significantly lower in BD patients compared to controls. However, the expression level of PCAT-1 was not significantly different between these two sets of samples. According to the ROC curve, PCAT-29 and MER11C had significant diagnostic power for the differentiation of BD patients from controls. Taken together, our results indicate dysregulation of two lncRNAs in patients with BD and the possible roles of these lncRNAs in the neuropathology of bipolar disorder.
- 23 July 2024
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-7
Open AccessThe expression analysis of long noncoding RNAs PCAT-1, PCAT-29, and MER11C in bipolar disorder
Long non-coding RNAs (lncRNAs) are transcripts with a length of usually more than 200 nucleotides (nt) that have promised functions in varied biological processes. lncRNAs participate in the regulation of differentiation, development, and function of the brain. Thus, their dysregulation might play important roles in the etiology of neurological disorders such as BD. In this study, the expression level of PCAT-1, PCAT-29, and MER11C lncRNAs was evaluated in the blood of BD patients compared to the control group. Peripheral blood mononuclear cells of 50 BD type I patients and 50 healthy individuals were isolated. The RNAs were extracted and cDNA was synthesized. Then, the expression level of the desired lncRNAs was measured through Real-Time PCR. The expression levels of PCAT-29 and MER11C lncRNAs were significantly lower in BD patients compared to controls. However, the expression level of PCAT-1 was not significantly different between these two sets of samples. According to the ROC curve, PCAT-29 and MER11C had significant diagnostic power for the differentiation of BD patients from controls. Taken together, our results indicate dysregulation of two lncRNAs in patients with BD and the possible roles of these lncRNAs in the neuropathology of bipolar disorder.
- Open Access
- 3 July 2024
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 15 (2)
Genotyping of rs1127354 and rs7270101 SNPs in Multiple Sclerosis Patients: Correlation with ITPA Gene Expression
Background: The ITPA gene plays a vital role in maintaining cellular homeostasis by regulating the levels of inosine triphosphate (ITP) and diphosphate (IDP) within cells. Dysregulation of ITPA can lead to an accumulation of ITP and IDP, which disrupts immune cell functions. Objective: This study aims to investigate, for the first time, the relationship between two specific genetic variations (94C- > A (rs1127354) and IVS2+21A → C (rs7270101) SNPs) and the expression of the ITPA gene in multiple sclerosis (MS) patients. Methods: The study included 112 MS patients and 109 healthy controls, with 32 patients and 30 controls randomly selected for genotyping. The expression of two ITPA transcripts in the peripheral blood mononuclear cells of all participants was measured using real-time PCR. Results: The study found no significant differences in the expression levels of transcript 1 and transcript 2 between MS patients and controls. Additionally, there were no significant differences in the genotypic and allele frequencies of the ITPA rs1127354 and rs7270101 SNPs in MS patients. Conclusions: These findings may contribute to the development of targeted therapies and personalized treatments for individuals with MS. Understanding the pathogenic potential and frequency distribution of these variants across diverse populations is crucial for elucidating their role in disease susceptibility and advancing personalized medicine approaches for multiple sclerosis and other autoimmune disorders.
- 3 July 2024
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 15 (2)
Open AccessGenotyping of rs1127354 and rs7270101 SNPs in Multiple Sclerosis Patients: Correlation with ITPA Gene Expression
Background: The ITPA gene plays a vital role in maintaining cellular homeostasis by regulating the levels of inosine triphosphate (ITP) and diphosphate (IDP) within cells. Dysregulation of ITPA can lead to an accumulation of ITP and IDP, which disrupts immune cell functions. Objective: This study aims to investigate, for the first time, the relationship between two specific genetic variations (94C- > A (rs1127354) and IVS2+21A → C (rs7270101) SNPs) and the expression of the ITPA gene in multiple sclerosis (MS) patients. Methods: The study included 112 MS patients and 109 healthy controls, with 32 patients and 30 controls randomly selected for genotyping. The expression of two ITPA transcripts in the peripheral blood mononuclear cells of all participants was measured using real-time PCR. Results: The study found no significant differences in the expression levels of transcript 1 and transcript 2 between MS patients and controls. Additionally, there were no significant differences in the genotypic and allele frequencies of the ITPA rs1127354 and rs7270101 SNPs in MS patients. Conclusions: These findings may contribute to the development of targeted therapies and personalized treatments for individuals with MS. Understanding the pathogenic potential and frequency distribution of these variants across diverse populations is crucial for elucidating their role in disease susceptibility and advancing personalized medicine approaches for multiple sclerosis and other autoimmune disorders.
- Open Access
- 10 June 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-19
An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers
Zinc finger antisense 1 (ZFAS1), a newly discovered long noncoding RNA, is expressed in various tissues and organs and has been introduced an oncogenic gene in human malignancies. In various cancers, ZFAS1 regulates apoptosis, cell proliferation, the cell cycle, migration, translation, rRNA processing, and spliceosomal snRNP assembly; targets signaling cascades; and interacts with transcription factors via binding to key proteins and miRNAs, with conflicting findings on its effect on these processes. ZFAS1 is elevated in different types of cancer, like colorectal, colon, osteosarcoma, and gastric cancer. Considering the ZFAS1 expression pattern, it also has the potential to be a diagnostic or prognostic marker in various cancers. The current review discusses the mode of action of ZFAS1 in various human cancers and its regulation function related to chemoresistance comprehensively, as well as the potential role of ZFAS1 as an effective and noninvasive cancer-specific biomarker in tumor diagnosis, prognosis, and treatment. We expected that the current review could fill the current scientific gaps in the ZFAS1-related cancer causative mechanisms and improve available biomarkers.
- 10 June 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-19
Open AccessAn update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers
Zinc finger antisense 1 (ZFAS1), a newly discovered long noncoding RNA, is expressed in various tissues and organs and has been introduced an oncogenic gene in human malignancies. In various cancers, ZFAS1 regulates apoptosis, cell proliferation, the cell cycle, migration, translation, rRNA processing, and spliceosomal snRNP assembly; targets signaling cascades; and interacts with transcription factors via binding to key proteins and miRNAs, with conflicting findings on its effect on these processes. ZFAS1 is elevated in different types of cancer, like colorectal, colon, osteosarcoma, and gastric cancer. Considering the ZFAS1 expression pattern, it also has the potential to be a diagnostic or prognostic marker in various cancers. The current review discusses the mode of action of ZFAS1 in various human cancers and its regulation function related to chemoresistance comprehensively, as well as the potential role of ZFAS1 as an effective and noninvasive cancer-specific biomarker in tumor diagnosis, prognosis, and treatment. We expected that the current review could fill the current scientific gaps in the ZFAS1-related cancer causative mechanisms and improve available biomarkers.
- 25 April 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (2) , 231-237
The oxidative stress-associated long non-coding RNAs in pancreatic cancer
- 25 April 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (2) , 231-237
The oxidative stress-associated long non-coding RNAs in pancreatic cancer